CD8A and neoplasm: In urothelial carcinoma, it was shown that patients with advanced disease (pT2, pT3, or pT4) who have higher numbers of CD8+ T cells within the tumor had longer survival than did patients with similar stage and fewer CD8+ T cells (19).